Skip to main content
NCBI home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 2005 Feb;90(Suppl 1):i26–i29. doi: 10.1136/adc.2004.059386

Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder

J Barton
PMCID: PMC1765270  PMID: 15665154

Full Text

The Full Text of this article is available as a PDF (59.9 KB).

Figure 1.

Figure 1

Open in a new tab

 Structure of atomoxetine.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BECK A. T., WARD C. H., MENDELSON M., MOCK J., ERBAUGH J. An inventory for measuring depression. Arch Gen Psychiatry. 1961 Jun;4:561–571. doi: 10.1001/archpsyc.1961.01710120031004. [DOI] [PubMed] [Google Scholar]
  2. Belle Donna J., Ernest C. Steven, Sauer John-Michael, Smith Brian P., Thomasson Holly R., Witcher Jennifer W. Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics. J Clin Pharmacol. 2002 Nov;42(11):1219–1227. doi: 10.1177/009127002762491307. [DOI] [PubMed] [Google Scholar]
  3. Bymaster Frank P., Katner Jason S., Nelson David L., Hemrick-Luecke Susan K., Threlkeld Penny G., Heiligenstein John H., Morin S. Michelle, Gehlert Donald R., Perry Kenneth W. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002 Nov;27(5):699–711. doi: 10.1016/S0893-133X(02)00346-9. [DOI] [PubMed] [Google Scholar]
  4. Conners C. K. Clinical use of rating scales in diagnosis and treatment of attention-deficit/hyperactivity disorder. Pediatr Clin North Am. 1999 Oct;46(5):857-70, vi. doi: 10.1016/s0031-3955(05)70159-0. [DOI] [PubMed] [Google Scholar]
  5. Conners C. K., Sitarenios G., Parker J. D., Epstein J. N. The revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998 Aug;26(4):257–268. doi: 10.1023/a:1022602400621. [DOI] [PubMed] [Google Scholar]
  6. Faraone S. V., Biederman J. Neurobiology of attention-deficit hyperactivity disorder. Biol Psychiatry. 1998 Nov 15;44(10):951–958. doi: 10.1016/s0006-3223(98)00240-6. [DOI] [PubMed] [Google Scholar]
  7. Finkelstein J. A., Davis R. L., Dowell S. F., Metlay J. P., Soumerai S. B., Rifas-Shiman S. L., Higham M., Miller Z., Miroshnik I., Pedan A. Reducing antibiotic use in children: a randomized trial in 12 practices. Pediatrics. 2001 Jul;108(1):1–7. doi: 10.1542/peds.108.1.1. [DOI] [PubMed] [Google Scholar]
  8. HAMILTON M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50–55. doi: 10.1111/j.2044-8341.1959.tb00467.x. [DOI] [PubMed] [Google Scholar]
  9. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967 Dec;6(4):278–296. doi: 10.1111/j.2044-8260.1967.tb00530.x. [DOI] [PubMed] [Google Scholar]
  10. Heil S. H., Holmes H. W., Bickel W. K., Higgins S. T., Badger G. J., Laws H. F., Faries D. E. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend. 2002 Jul 1;67(2):149–156. doi: 10.1016/s0376-8716(02)00053-4. [DOI] [PubMed] [Google Scholar]
  11. Kratochvil C. J., Bohac D., Harrington M., Baker N., May D., Burke W. J. An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2001 Summer;11(2):167–170. doi: 10.1089/104454601750284072. [DOI] [PubMed] [Google Scholar]
  12. Kratochvil Christopher J., Heiligenstein John H., Dittmann Ralf, Spencer Thomas J., Biederman Joseph, Wernicke Joachim, Newcorn Jeffrey H., Casat Charles, Milton Denai, Michelson David. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002 Jul;41(7):776–784. doi: 10.1097/00004583-200207000-00008. [DOI] [PubMed] [Google Scholar]
  13. Kratochvil Christopher J., Heiligenstein John H., Dittmann Ralf, Spencer Thomas J., Biederman Joseph, Wernicke Joachim, Newcorn Jeffrey H., Casat Charles, Milton Denai, Michelson David. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry. 2002 Jul;41(7):776–784. doi: 10.1097/00004583-200207000-00008. [DOI] [PubMed] [Google Scholar]
  14. Kratochvil Christopher J., Vaughan Brigette S., Harrington Martin J., Burke William J. Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Pharmacother. 2003 Jul;4(7):1165–1174. doi: 10.1517/14656566.4.7.1165. [DOI] [PubMed] [Google Scholar]
  15. Mannuzza S., Klein R. G., Bessler A., Malloy P., LaPadula M. Adult psychiatric status of hyperactive boys grown up. Am J Psychiatry. 1998 Apr;155(4):493–498. doi: 10.1176/ajp.155.4.493. [DOI] [PubMed] [Google Scholar]
  16. Michelson David, Adler Lenard, Spencer Thomas, Reimherr Frederick W., West Scott A., Allen Albert J., Kelsey Douglas, Wernicke Joachim, Dietrich Anthony, Milton Denái. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003 Jan 15;53(2):112–120. doi: 10.1016/s0006-3223(02)01671-2. [DOI] [PubMed] [Google Scholar]
  17. Michelson David, Allen Albert J., Busner Joan, Casat Charles, Dunn David, Kratochvil Christopher, Newcorn Jeffrey, Sallee F. Randy, Sangal R. Bart, Saylor Keith. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002 Nov;159(11):1896–1901. doi: 10.1176/appi.ajp.159.11.1896. [DOI] [PubMed] [Google Scholar]
  18. Sauer John-Michael, Long Amanda J., Ring Barbara, Gillespie Jennifer S., Sanburn Nathan P., DeSante Karl A., Petullo David, VandenBranden Mark R., Jensen Charles B., Wrighton Steven A. Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome. J Pharmacol Exp Ther. 2003 Nov 10;308(2):410–418. doi: 10.1124/jpet.103.058727. [DOI] [PubMed] [Google Scholar]
  19. Sauer John-Michael, Ponsler G. Douglas, Mattiuz Edward L., Long Amanda J., Witcher Jennifer W., Thomasson Holly R., Desante Karl A. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab Dispos. 2003 Jan;31(1):98–107. doi: 10.1124/dmd.31.1.98. [DOI] [PubMed] [Google Scholar]
  20. Spencer T., Biederman J., Heiligenstein J., Wilens T., Faries D., Prince J., Faraone S. V., Rea J., Witcher J., Zervas S. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol. 2001 Fall;11(3):251–265. doi: 10.1089/10445460152595577. [DOI] [PubMed] [Google Scholar]
  21. Spencer T., Biederman J., Wilens T., Harding M., O'Donnell D., Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry. 1996 Apr;35(4):409–432. doi: 10.1097/00004583-199604000-00008. [DOI] [PubMed] [Google Scholar]
  22. Spencer T., Biederman J., Wilens T., Prince J., Hatch M., Jones J., Harding M., Faraone S. V., Seidman L. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1998 May;155(5):693–695. doi: 10.1176/ajp.155.5.693. [DOI] [PubMed] [Google Scholar]
  23. Spencer Thomas, Heiligenstein John H., Biederman Joseph, Faries Douglas E., Kratochvil Christopher J., Conners C. Keith, Potter William Z. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002 Dec;63(12):1140–1147. doi: 10.4088/jcp.v63n1209. [DOI] [PubMed] [Google Scholar]
  24. Swanson J. M., Kraemer H. C., Hinshaw S. P., Arnold L. E., Conners C. K., Abikoff H. B., Clevenger W., Davies M., Elliott G. R., Greenhill L. L. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry. 2001 Feb;40(2):168–179. doi: 10.1097/00004583-200102000-00011. [DOI] [PubMed] [Google Scholar]
  25. Taylor E., Chadwick O., Heptinstall E., Danckaerts M. Hyperactivity and conduct problems as risk factors for adolescent development. J Am Acad Child Adolesc Psychiatry. 1996 Sep;35(9):1213–1226. doi: 10.1097/00004583-199609000-00019. [DOI] [PubMed] [Google Scholar]
  26. Wender P. H., Reimherr F. W., Wood D., Ward M. A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. Am J Psychiatry. 1985 May;142(5):547–552. doi: 10.1176/ajp.142.5.547. [DOI] [PubMed] [Google Scholar]
  27. Wernicke J. F., Kratochvil Christopher J. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry. 2002;63 (Suppl 12):50–55. [PubMed] [Google Scholar]
  28. Wernicke Joachim F., Adler Lenard, Spencer Thomas, West Scott A., Allen Albert J., Heiligenstein John, Milton Denái, Ruff Dustin, Brown W. Jeffrey, Kelsey Douglas. Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. J Clin Psychopharmacol. 2004 Feb;24(1):30–35. doi: 10.1097/01.jcp.0000104907.75206.c2. [DOI] [PubMed] [Google Scholar]
  29. Wernicke Joachim F., Faries Douglas, Girod Donald, Brown Jeffrey, Gao Haitao, Kelsey Douglas, Quintana Humberto, Lipetz Robert, Michelson David, Heiligenstein John. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf. 2003;26(10):729–740. doi: 10.2165/00002018-200326100-00006. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES